A multicenter trial assessing the impact of Lp(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis (Lp(a)FRONTIERS CAVS) (NCT05646381)

Educational Partners and Supporters

AstraZeneca has provided a sponsorship grant towards this independent programme.

(Founding Partner)

Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.